Kenneth Burnham, MD
Advanced Heart Failure and Transplant Cardiology · Mobile, ALNPI 1164462321
Payments from drug & device makers
Across 792 payments — averaging $562.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$108K
- Novartis$68K
- Boehringer Ingelheim$62K
- AstraZeneca$61K
- Pfizer$60K
- Lexicon Pharmaceuticals, Inc.$49K
- plus $37K from 27 others
What the payments were for
- Consulting fees$11,5153%
- Speaking & faculty fees$390,35088%
- Travel & lodging$24,9206%
- Food & beverage$18,6134%
- Education$3160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 108 | $108,480 |
| Novartis | 81 | $68,182 |
| Boehringer Ingelheim | 97 | $62,270 |
| AstraZeneca | 100 | $60,968 |
| Pfizer | 64 | $60,297 |
| Lexicon Pharmaceuticals, Inc. | 69 | $48,821 |
| Lilly USA, LLC | 10 | $10,588 |
| Alnylam Pharmaceuticals Inc. | 44 | $7,901 |
| Bayer | 31 | $5,452 |
| Actelion Pharmaceuticals US, Inc. | 37 | $5,226 |
| Cvrx, Inc. | 16 | $4,396 |
| Abbott | 13 | $544 |
| Scpharmaceuticals Inc. | 32 | $503 |
| Johnson & Johnson | 25 | $352 |
| Merck | 15 | $292 |
| Amgen | 9 | $229 |
| United Therapeutics Corporation | 7 | $225 |
| Atricure, Inc. | 4 | $181 |
| Abiomed | 4 | $175 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Sensible Medical Innovations Inc | 3 | $98 |
| Bridgebio Pharma, Inc. | 2 | $66 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $60 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $59 |
| Lantheus Medical Imaging, Inc. | 3 | $49 |
| Novo Nordisk | 2 | $34 |
| Vivaquant Inc, Dba Rhythm Express | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $23 |
| Medtronic | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Liquidia Technologies, Inc. | 1 | $15 |
| Akcea Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAMZYOS$94,505
- JARDIANCE$69,901
- ENTRESTO$61,158
- FARXIGA$51,488
- Inpefa$47,524
- VYNDAQEL$34,207
- ELIQUIS$30,458
- LOKELMA$7,429
- AMVUTTRA$6,165
- Kerendia$4,890
- UPTRAVI$4,440
- OPSUMIT$4,440
- Barostim Neo System$3,978
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$150
- ONPATTRO$125
- NEXLIZET$125
- NEXLETOL$125
- SYNERGY ABLATION SYSTEM$123
- FUROSCIX$122
How this compares
Too few advanced heart failure and transplant cardiology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 1,133 | $1,192,899 |
| Orenitram ErTreprostinil Diolamine | 30 | $1,158,196 |
| VyndamaxTafamidis | 38 | $1,111,915 |
| AdempasRiociguat | 75 | $1,084,842 |
| Tyvaso DpiTreprostinil | 39 | $938,730 |
| EliquisApixaban | 972 | $894,623 |
| CamzyosMavacamten | 82 | $664,305 |
| OpsumitMacitentan | 44 | $583,455 |
| FarxigaDapagliflozin Propanediol | 708 | $564,323 |
| JardianceEmpagliflozin | 295 | $291,473 |
| LetairisAmbrisentan | 15 | $244,089 |
| Ambrisentan | 48 | $191,625 |
| XareltoRivaroxaban | 135 | $156,731 |
| FuroscixFurosemide | 11 | $55,474 |
| Repatha SureclickEvolocumab | 49 | $50,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $60,297 | $2,006,5381,010 claims |
| NovartisEntresto | $68,182 | $1,192,8991,133 claims |
| BayerAdempas | $5,452 | $1,084,84275 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $108,480 | $664,30582 claims |
| AstraZenecaFarxiga, Brilinta | $60,968 | $584,252747 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $5,226 | $583,45544 claims |
| Boehringer IngelheimJardiance | $62,270 | $291,473295 claims |
| Johnson & JohnsonXarelto | $352 | $156,731135 claims |
| Scpharmaceuticals Inc.Furoscix | $503 | $55,47411 claims |
| MerckVerquvo | $292 | $35,96342 claims |
| Novo NordiskWegovy | $34 | $23,25718 claims |
| AmgenCorlanor | $229 | $15,80625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Mobile
- Luanda GrazetteMobile$309K
- Jose TallajBirmingham$646K
- Kaushik JainHuntsville$477K
- Ayman Haj AsaadBirmingham$46K
- David SmullDecatur$20K
- Indranee RajapreyarBirmingham$11K
- Heriberto Matos SantanaBirmingham$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.